An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

VORANIGO®

Drug Information Related Patent

Hold Company

SERVIER

Learn More

Dosage and Administration

TABLET;ORAL

Specification

10MG; 40MG

Indication

Voranigo® is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.

Use

Instructions for Use

API

VORASIDENIB

API Structure

We Supply

VORASIDENIB

Drug Patent

Patent No	Expiration Date
10172864	2034/7/11
11345677	2039/1/16
11844758	2035/12/4
9579324	2034/7/11

API Patent

Patent No	Expiration Date
10172864	2034/7/11
11345677	2039/1/16
11844758	2035/12/4
9579324	2034/7/11

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION